- Home
- LICY vs ANL Comparison
LICY vs ANL Comparison
Compare LICY & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICY
- ANL
- Stock Information
- Founded
- LICY 2016
- ANL 2004
- Country
- LICY Canada
- ANL Cayman Islands
- Employees
- LICY N/A
- ANL N/A
- Industry
- LICY Environmental Services
- ANL
- Sector
- LICY Industrials
- ANL
- Exchange
- LICY Nasdaq
- ANL Nasdaq
- Market Cap
- LICY 83.8M
- ANL 72.7M
- IPO Year
- LICY N/A
- ANL 2023
- Fundamental
- Price
- LICY $2.41
- ANL $3.16
- Analyst Decision
- LICY Hold
- ANL Strong Buy
- Analyst Count
- LICY 3
- ANL 2
- Target Price
- LICY $5.36
- ANL $9.00
- AVG Volume (30 Days)
- LICY 2.3M
- ANL 27.1K
- Earning Date
- LICY 11-07-2024
- ANL 08-08-2024
- Dividend Yield
- LICY N/A
- ANL N/A
- EPS Growth
- LICY N/A
- ANL N/A
- EPS
- LICY N/A
- ANL N/A
- Revenue
- LICY $27,400,000.00
- ANL $5,000,000.00
- Revenue This Year
- LICY $48.13
- ANL N/A
- Revenue Next Year
- LICY $18.15
- ANL N/A
- P/E Ratio
- LICY N/A
- ANL N/A
- Revenue Growth
- LICY N/A
- ANL N/A
- 52 Week Low
- LICY $1.22
- ANL $1.85
- 52 Week High
- LICY $15.36
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- LICY 46.18
- ANL 66.74
- Support Level
- LICY $2.69
- ANL $2.00
- Resistance Level
- LICY $4.98
- ANL $3.89
- Average True Range (ATR)
- LICY 0.57
- ANL 0.38
- MACD
- LICY -0.04
- ANL 0.14
- Stochastic Oscillator
- LICY 13.60
- ANL 61.74
About LICY Li-Cycle Holdings Corp.
Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.